Cleveland Clinic's 20th Annual ASH Review

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Cleveland Clinic's 20th Annual ASH Review

http://www.clevelandclinicmeded.com/live/courses/ashreview/

Benign Hematology
Malignant Hematology
Events

Playback speed

10 seconds

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 and for Which Pts? Does E1912 Suggest Ibrutinib Can Be Considered a Time Limited Therapy?

By Cleveland Clinic's 20th Annual ASH Review FEATURING Anthony R. Mato

343 views

April 14, 2020

Comments 0

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

The First Treatment Choice Matters

Feat. A. Ip

Malignant Hematology

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…

Cleveland Clinic's 20th Annual ASH Review

H. Carraway

21 views

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…

Cleveland Clinic's 20th Annual ASH Review

H. Carraway

26 views

2019 ASH Review on Anemia in Myelofibrosis: Luspatercept Improvement…

Cleveland Clinic's 20th Annual ASH Review

S. Mukherjee

18 views

ASH 2019 Review on Treating Myelofibrosis in the Setting of Thromboc…

Cleveland Clinic's 20th Annual ASH Review

S. Mukherjee

20 views

2019 ASH Review on Limited Stage DLBCL: Can We Use PET Scan to Tailo…

Cleveland Clinic's 20th Annual ASH Review

B. Hill

533 views

2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of …

Cleveland Clinic's 20th Annual ASH Review

B. Hill

124 views

2019 ASH Review on MCL: Can Anti-CD19 CAR-T Cell Therapy Be Used for…

Cleveland Clinic's 20th Annual ASH Review

B. Hill

164 views

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 an…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

343 views

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Nov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

174 views

2019 ASH Review on Combinations or Sequences of Targeted Agents in C…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

78 views

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

27 views

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Cov…

Cleveland Clinic's 20th Annual ASH Review

A. Mato

32 views

2019 ASH Review: Should High-risk Smoldering Myeloma Be Treated? Evi…

Cleveland Clinic's 20th Annual ASH Review

F. Anwer

21 views

2019 ASH Review on Newly Diagnosed Multiple Myeloma: VRD-Dara vs. VR…

Cleveland Clinic's 20th Annual ASH Review

F. Anwer

82 views

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier…

Cleveland Clinic's 20th Annual ASH Review

F. Anwer

122 views